iTANK
Elicera CEO: “These early results are very encouraging”
Elicera Therapeutics has communicated promising preliminary data from its Phase I/IIa CARMA study with ELC-301, demonstrating complete metabolic response...
Elicera CEO: "2025 is a key year for us"
For Elicera, 2024 meant important clinical advances and...
Elicera CEO: “ELC-100 is different from all other standard treatments”
Elicera CEO: “One of the biggest milestones in our history”
Elicera Therapeutics has officially entered clinical...
Elicera nears study start of its first clinical CAR T-cell trial CARMA
Elicera Therapeutics is preparing to initiate its first...
Emission to take Elicera's ELC-301 through clinical trial
Cell and gene therapy specialist Elicera Therapeutics is on its way...
Elicera CEO: "iTANK has high potential in the treatment of solid tumors"
Elicera's Q3 report was a read packed with updates...
Elicera Therapeutics secures important EU patent
The European Patent Office intends to approve Elicera's patent application...
Well-funded Elicera prepared for clinic and business development
Cell and gene therapy company Elicera Therapeutics has made important...
Janssen's CAR T agreement supports Elicera's vision
Janssen and Cellular Biomedicine Group agreement worth 245...
Elicera Therapeutics on the Danish Medicines Agency's conditional approval
At the end of April, gene and cell therapy company Elicera received...
Elicera on the potential of CAR T cells outside of blood cancer
CAR T-cell therapy is an emerging form of immunotherapy...